FMR LLC & Abigail Johnson Report 14.999% Stake in Viking Therapeutics
Ticker: VKTX · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1607678
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**FMR LLC still owns nearly 15% of Viking Therapeutics, showing continued institutional interest.**
AI Summary
FMR LLC, a major investment firm, and its Chairman and CEO, Abigail P. Johnson, have updated their ownership stake in Viking Therapeutics, Inc. (VKNG) through an SC 13G/A filing on February 9, 2024. They collectively beneficially own 15,004,340 shares of common stock, representing 14.999% of the company. This matters to investors because it shows a significant, slightly reduced, but still substantial, passive ownership by a large institutional investor, indicating continued confidence in Viking Therapeutics' long-term prospects.
Why It Matters
This filing indicates that a major institutional investor, FMR LLC, continues to hold a significant, albeit slightly adjusted, passive stake in Viking Therapeutics, which can influence market perception and stability.
Risk Assessment
Risk Level: low — This filing is an amendment to a passive ownership report, indicating no immediate change in control or significant new risks.
Analyst Insight
Investors should note that a major institutional investor, FMR LLC, continues to hold a substantial, passive stake in Viking Therapeutics, suggesting long-term confidence without indicating any immediate strategic changes or activist intent.
Key Numbers
- 15,004,340 — Shares Beneficially Owned (Total common stock shares of Viking Therapeutics owned by FMR LLC and Abigail P. Johnson.)
- 14.999% — Percent of Class (The percentage of Viking Therapeutics' common stock class owned by FMR LLC and Abigail P. Johnson.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, Chairman and CEO of FMR LLC
- Viking Therapeutics, Inc. (company) — issuer of the common stock
- 15,004,340 (dollar_amount) — total shares beneficially owned
- 14.999% (dollar_amount) — percentage of class owned
Forward-Looking Statements
- FMR LLC will maintain a significant, passive ownership stake in Viking Therapeutics, Inc. for the foreseeable future. (FMR LLC) — high confidence, target: 2025-02-09
FAQ
Who is the primary entity filing this SC 13G/A amendment?
The primary entity filing this SC 13G/A amendment is FMR LLC, a parent holding company, as stated in Item 2(a) and Item 3 of the filing.
What is the total number of Viking Therapeutics, Inc. common stock shares beneficially owned by FMR LLC and Abigail P. Johnson?
FMR LLC and Abigail P. Johnson collectively beneficially own 15,004,340 shares of Viking Therapeutics, Inc. common stock, as reported in Item 4(a) and Item 7 for both reporting persons.
What percentage of Viking Therapeutics, Inc.'s common stock class do FMR LLC and Abigail P. Johnson own?
FMR LLC and Abigail P. Johnson own 14.999% of the common stock class of Viking Therapeutics, Inc., as indicated in Item 4(b) and Item 11 for both reporting persons.
What is the CUSIP number for Viking Therapeutics, Inc. common stock mentioned in the filing?
The CUSIP number for Viking Therapeutics, Inc. common stock is 92686J106, as stated in the filing's cover page and Item 2(e).
Where are Viking Therapeutics, Inc.'s principal executive offices located according to the filing?
Viking Therapeutics, Inc.'s principal executive offices are located at 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA 92121 US, as detailed in Item 1(b) of the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Viking Therapeutics, Inc. (VKTX).